The company has not filed an annual or quarterly report since its Q2 FY2023 10-Q, filed Aug 3, 2023. Its latest SEC filing is a 15-12G from Oct 2, 2023.
10-Q for Q2 FY2023, filed Aug 3, 2023
The sections below describe the company as of the FY2022 annual report.
Sells NUZYRA, an oral and intravenous antibiotic for adult pneumonia and serious skin infections, through specialty distributors and pharmacies; licenses SEYSARA acne-treatment rights to Almirall.
10-K for FY2022, filed Mar 16, 2023We are a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for…View ↗
SEYSARA® (sarecycline) is an FDA-approved product which we have exclusively licensed in the U.S. and the People’s Republic of China, Hong…View ↗
The Company sells its product principally to a limited number of specialty distributors and specialty pharmacy providers in the U.S. These…View ↗
Specialty distributors and pharmacy providers pay for NUZYRA when the product is delivered; BARDA funds development work and buys treatment courses, while Paratek earns royalties on SEYSARA sales licensed to Almirall.
10-K for FY2022, filed Mar 16, 2023The Company sells its product principally to a limited number of specialty distributors and specialty pharmacy providers in the U.S. These…View ↗
Revenues from product sales are recognized when the customer obtains control of the Company’s product, which typically occurs once the…View ↗
In December 2019, we entered into the BARDA contract, which is a five-year contract with an option to extend to ten years. The BARDA…View ↗
The second procurement, the purchase of an additional 2,500 treatment courses of NUZYRA for a total of $36.4 million, was delivered to and…View ↗
We received FDA approval for NUZYRA in October 2018 and launched NUZYRA in the U.S. in February 2019. Additionally, FDA approval was…View ↗
$160.3M
10-K for FY2022, filed Mar 16, 2023
$160.3M ↗
Paratek sells NUZYRA mainly to U.S. specialty distributors and specialty pharmacy providers, which resell it to health care providers or dispense it to patients. Hospitals and outpatient infusion centers can also buy under agreements, directly or through group purchasing organizations.
10-K for FY2022, filed Mar 16, 2023
No. It lost $63.6M in FY2022.
10-K for FY2022, filed Mar 16, 2023
10-Q for Q2 FY2023, filed Aug 3, 2023
−$14.6MView ↗
8-K, filed Sep 21, 2023
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.View ↗
Grew. Revenue grew 9.4x in 4 years, from $17.1M in FY2018 to $160.3M in FY2022, about 75% a year.
SEYSARA license territory The latest report adds Taiwan to the territories covered by Almirall's SEYSARA license, alongside China, Hong Kong, and Macau.
Competes with Abbott Laboratories, Pfizer, Merck Pharmaceuticals, Abbvie, Melinta Therapeutics, Cumberland Therapeutics, Bayer, Johnson & Johnson, F. Hoffman-La Roche, Nabriva Therapeutics, Crystal Genomics, GSK, TaiGen Biotechnology, and Cellceutix
10-K for FY2022, filed Mar 16, 2023NUZYRA competes with other antibiotics in the serious bacterial skin infection market. These include, but are not limited to, vancomycin…View ↗
Loading...
